OF
NBIX icon

Optimize Financial’s Neurocrine Biosciences NBIX Stock Holding History

Optimize Financial’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$456K Buy
3,459
+476
+16% +$63.2K 0.22% 138
2025
Q4 		$423K Buy
2,983
+40
+1% +$5.79K 0.21% 196
2025
Q3 		$413K Buy
+2,943
New +$399K 0.22% 201
2025
Q1 		– Sell
-1,834
Closed -$250K – 263
2024
Q4 		$250K Buy
+1,834
New +$227K 0.19% 167

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Optimize Financial's NBIX Position: Q1 2026 in Review

Optimize Financial increased its Neurocrine Biosciences (NBIX) stake by 16% in Q1 2026, buying an estimated $63.2K and bringing the position to 3,459 shares worth $456K. The position accounts for 0.22% of the portfolio, ranked #138.

Optimize Financial first reported a position in NBIX in Q4 2024 and has held it in 4 quarters since. 694 funds tracked by Wall St. Rank hold NBIX as of Q1 2026.

  • Optimize Financial held 3,459 shares of Neurocrine Biosciences worth $456K as of Q1 2026.
  • Optimize Financial bought 476 Neurocrine Biosciences shares in Q1 2026, an estimated $63.2K.
  • Neurocrine Biosciences made up 0.22% of Optimize Financial's portfolio in Q1 2026, its #138 holding.
  • Optimize Financial first reported a position in Neurocrine Biosciences in Q4 2024 and has held it in 4 quarters since.
  • 694 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2026.

Based on Optimize Financial's 13F filing for Q1 2026, filed 12 May 2026.